News Industry News Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate) November 29, 2015
News Conference News AHA 2015 Reversal Agents Safely Stop Effects of Novel Oral Anticoagulants Yael L. Maxwell November 10, 2015
News Conference News AHA 2015 Is Watchman Cost-effective? That Depends Where You Look Todd Neale November 07, 2015
News Daily News First NOAC Antidote, Idarucizumab, Approved; Likely Won’t Hold Up Interventions Todd Neale October 26, 2015
News Daily News Aprobado el Idarucizumab, Primer Antídoto de NOAC; El Deseo es no Demorar las Intervenciones Todd Neale October 26, 2015
News Industry News FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa October 20, 2015
Presentation TCT 2015 The RE-DUAL PCI Trial (Dabigatran in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status Presenter: Pascal Vranckx, Deepak L. Bhatt October 14, 2015
Presentation TCT 2015 Dabigatran: Analysis of Efficacy, Safety, and Special Considerations (Including Reversal Agents) Presenter: Lisa K. Jennings, Matthew T. Roe, Pascal Vranckx October 14, 2015
News Industry News CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®) September 25, 2015
News Conference News ESC 2015 ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff September 09, 2015
News Conference News ESC 2015 NSAIDs Plus Anticoagulants a Bad Combination Caitlin E. Cox September 01, 2015
News Industry News First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate) July 29, 2015
News Daily News Después de Sufrir un Embolismo Pulmonar el Beneficio de la Anticoagulación Secundaria No se Mantiene L.A. McKeown July 13, 2015
News Daily News After Pulmonary Embolism, Benefit of Secondary Anticoagulation Does Not Persist L.A. McKeown July 13, 2015
News Daily News RE-VERSE AD: El Antídoto de Dabigatran, Seguro y Eficaz en un Análisis Provisional June 25, 2015
News Daily News RE-VERSE AD: Dabigatran Antidote Appears Safe, Effective in Interim Analysis June 25, 2015